6533b855fe1ef96bd12afd7a

RESEARCH PRODUCT

Intravitreal pegaptanib for refractory macular edema secondary to retinal vein occlusion

David SalomPatricia UdaondoMaria Garcia-pousManuel Díaz-llopisSalvador Garcia-delpech

subject

medicine.medical_specialtyVisual acuityRetinal VeinTriamcinolone acetonideBevacizumabgenetic structuresBCVAPegaptanibCase Reportpegaptanib sodiumOphthalmologymedicinePegaptanib SodiumMacular edemaBRVObusiness.industryClinical OphthalmologyRE1-994medicine.diseaseeye diseasesSurgeryOphthalmologyMacugen®Branch retinal vein occlusionsense organsmedicine.symptombusinessmedicine.drug

description

Patricia Udaondo1,2, Salvador Garcia-Delpech1,3, David Salom1,3, Maria Garcia-Pous1,3, Manuel Diaz-Llopis1,31Nuevo Hospital Universitario y Politecnico La Fe, Valencia, Spain; 2University Cardenal Herrera CEU, Valencia, Spain; 3Faculty of Medicine, University of Valencia, Valencia, SpainPurpose: To assess the efficacy of intravitreal Pegaptanib sodium (Macugen®) injection in the management of refractory macular edema secondary to branch retinal vein occlusion.Methods: This is a prospective, nonrandomized, interventional case series. Five eyes of five patients with macular edema refractory to either bevacizumab or triamcinolone were treated with intravitreal injection of Pegaptanib sodium.Results: After three months follow-up, both visual acuity and macular edema, measured by optical coherence tomography and fluorescence angiography, dramatically improved.Conclusion: Pegaptanib sodium is a safe and efficacy treatment for macular edema secondary to branch retinal vein occlusion.Keywords: Macugen®, BRVO, BCVA, pegaptanib sodium

yearjournalcountryeditionlanguage
2011-07-01
http://www.scopus.com/inward/record.url?eid=2-s2.0-79960428405&partnerID=MN8TOARS